Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Sevabertinib on Midazolam PK in Healthy Participants
NCT06360211Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Primary endpoints: Maximum observed concentration of midazolam at Day 14 and Area under the curve of midazolam at Day 14. Started Apr 2024; status: completed.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06360211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360211.